Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Vascular Medicine
Volume 2019, Article ID 6853135, 4 pages
Case Series

An Off-Label Use of a Unibody Aortic Stent-Graft System for the Treatment of Infrarenal Abdominal Aortic Dissections

1Department of Vascular Surgery, Royal Perth Hospital, Perth, Western Australia, Australia
2Department of Vascular Surgery, Hollywood Private Hospital, Western Australia, Australia
3School of Medicine, University of Western Australia, Perth, Western Australia, Australia
4Perth Institute of Vascular Surgery, Perth, Western Australia, Australia

Correspondence should be addressed to Joseph Faraj;

Received 8 March 2019; Accepted 24 March 2019; Published 8 April 2019

Academic Editor: Nikolaos Papanas

Copyright © 2019 Joseph Faraj et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Infrarenal abdominal aortic dissections (IAAD) are exceedingly rare, accounting for 1-4% of all aortic dissections. The evidence is scarce on how to best manage IAAD when they become symptomatic. Two main interventional approaches exist, open surgery and the endovascular approach. Conventional stent-graft systems make it difficult to treat nonaneurysmal aortic disease due to limb competition in a narrow distal aorta. Thus, we present a novel use of the Endologix Anatomical Fixation 2 (AFX2) Abdominal Aortic Aneurysm (AAA) endograft system for the treatment of four patients with IAAD. We also highlight an individual case study that was treated with an alternative endovascular approach and the complications that followed. This was to highlight and compare our successful experience with Endologix AFX2 AAA endograft system. There were multiple benefits for choosing this stent-graft; however the main advantage is its suitability in the narrow distal aorta. Our aim was to highlight an alternative endovascular approach for the successful treatment of a rare, challenging, and potentially fatal pathology.